StreetInsider.com News Articles

Tenaya Therapeutics shows positive gene therapy trial results for heart condition

Wed, 03 Jun 2026 07:02:48 -0400

Tenaya Therapeutics Inc. (NASDAQ: TNYA) reported interim data from its MyPEAK-1 Phase 1b/2 clinical trial showing that gene therapy treatment TN-201 improved cardiac function and reduced symptoms in patients with MYBPC3-associated hypertrophic cardiomyopathy.

The trial evaluated seven patients across two dose levels of TN-201. Six evaluable patients demonstrated reductions in left ventricular mass index, a measure of heart muscle thickening that defines the condition. All patients showed improvements in multiple disease parameters including cardiac troponin levels and symptom burden assessments.

Five of six patients improved by at least one class on the New York Heart Association classification scale, with all five now

Tenaya Therapeutics shows positive gene therapy trial results for heart condition

Wed, 03 Jun 2026 07:02:48 -0400

Five of six patients improved by at least one class on the New York Heart Association classification scale, with all five now

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Sym

Wed, 03 Jun 2026 07:00:00 -0400

All Evaluable Patients Achieved Improvements in Multiple Hallmarks of
MYBPC3-Associated HCM

Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom Relief and Improved Cardiac Function at Earlier Timepoint

TN-201 Granted PRIME Designation by EMA; and Pediatric Indication Accepted into FDA’s Rare Disease Evidence Principles Process

Tenaya Management to Host a Webcast Conference Call to Review Results at 8:00 a.m. ET / 5:00 a.m. PT

SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA) reported

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Sym

Wed, 03 Jun 2026 07:00:00 -0400

All Evaluable Patients Achieved Improvements in Multiple Hallmarks of
MYBPC3-Associated HCM

Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom Relief and Improved Cardiac Function at Earlier Timepoint

TN-201 Granted PRIME Designation by EMA; and Pediatric Indication Accepted into FDA’s Rare Disease Evidence Principles Process

Tenaya Management to Host a Webcast Conference Call to Review Results at 8:00 a.m. ET / 5:00 a.m. PT

SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA) reported

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Sym

Wed, 03 Jun 2026 07:00:00 -0400

All Evaluable Patients Achieved Improvements in Multiple Hallmarks of
MYBPC3-Associated HCM

Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom Relief and Improved Cardiac Function at Earlier Timepoint

TN-201 Granted PRIME Designation by EMA; and Pediatric Indication Accepted into FDA’s Rare Disease Evidence Principles Process

Tenaya Management to Host a Webcast Conference Call to Review Results at 8:00 a.m. ET / 5:00 a.m. PT

SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA) reported

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Sym

Wed, 03 Jun 2026 07:00:00 -0400

All Evaluable Patients Achieved Improvements in Multiple Hallmarks of
MYBPC3-Associated HCM

Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom Relief and Improved Cardiac Function at Earlier Timepoint

TN-201 Granted PRIME Designation by EMA; and Pediatric Indication Accepted into FDA’s Rare Disease Evidence Principles Process

Tenaya Management to Host a Webcast Conference Call to Review Results at 8:00 a.m. ET / 5:00 a.m. PT

SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA) reported

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Sym

Wed, 03 Jun 2026 07:00:00 -0400

All Evaluable Patients Achieved Improvements in Multiple Hallmarks of
MYBPC3-Associated HCM

Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom Relief and Improved Cardiac Function at Earlier Timepoint

TN-201 Granted PRIME Designation by EMA; and Pediatric Indication Accepted into FDA’s Rare Disease Evidence Principles Process

Tenaya Management to Host a Webcast Conference Call to Review Results at 8:00 a.m. ET / 5:00 a.m. PT

SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA) reported

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Sym

Wed, 03 Jun 2026 07:00:00 -0400

All Evaluable Patients Achieved Improvements in Multiple Hallmarks of
MYBPC3-Associated HCM

Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom Relief and Improved Cardiac Function at Earlier Timepoint

TN-201 Granted PRIME Designation by EMA; and Pediatric Indication Accepted into FDA’s Rare Disease Evidence Principles Process

Tenaya Management to Host a Webcast Conference Call to Review Results at 8:00 a.m. ET / 5:00 a.m. PT

SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA) reported

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Sym

Wed, 03 Jun 2026 07:00:00 -0400

All Evaluable Patients Achieved Improvements in Multiple Hallmarks of
MYBPC3-Associated HCM

Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom Relief and Improved Cardiac Function at Earlier Timepoint

TN-201 Granted PRIME Designation by EMA; and Pediatric Indication Accepted into FDA’s Rare Disease Evidence Principles Process

Tenaya Management to Host a Webcast Conference Call to Review Results at 8:00 a.m. ET / 5:00 a.m. PT

SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA) reported

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Sym

Wed, 03 Jun 2026 07:00:00 -0400

All Evaluable Patients Achieved Improvements in Multiple Hallmarks of
MYBPC3-Associated HCM

Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom Relief and Improved Cardiac Function at Earlier Timepoint

TN-201 Granted PRIME Designation by EMA; and Pediatric Indication Accepted into FDA’s Rare Disease Evidence Principles Process

Tenaya Management to Host a Webcast Conference Call to Review Results at 8:00 a.m. ET / 5:00 a.m. PT

SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA) reported

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Sym

Wed, 03 Jun 2026 07:00:00 -0400

All Evaluable Patients Achieved Improvements in Multiple Hallmarks of
MYBPC3-Associated HCM

Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom Relief and Improved Cardiac Function at Earlier Timepoint

TN-201 Granted PRIME Designation by EMA; and Pediatric Indication Accepted into FDA’s Rare Disease Evidence Principles Process

Tenaya Management to Host a Webcast Conference Call to Review Results at 8:00 a.m. ET / 5:00 a.m. PT

SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA) reported

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Sym

Wed, 03 Jun 2026 07:00:00 -0400

All Evaluable Patients Achieved Improvements in Multiple Hallmarks of
MYBPC3-Associated HCM

Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom Relief and Improved Cardiac Function at Earlier Timepoint

TN-201 Granted PRIME Designation by EMA; and Pediatric Indication Accepted into FDA’s Rare Disease Evidence Principles Process

Tenaya Management to Host a Webcast Conference Call to Review Results at 8:00 a.m. ET / 5:00 a.m. PT

SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA) reported

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Sym

Wed, 03 Jun 2026 07:00:00 -0400

All Evaluable Patients Achieved Improvements in Multiple Hallmarks of
MYBPC3-Associated HCM

Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom Relief and Improved Cardiac Function at Earlier Timepoint

TN-201 Granted PRIME Designation by EMA; and Pediatric Indication Accepted into FDA’s Rare Disease Evidence Principles Process

Tenaya Management to Host a Webcast Conference Call to Review Results at 8:00 a.m. ET / 5:00 a.m. PT

SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA) reported

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Sym

Wed, 03 Jun 2026 07:00:00 -0400

All Evaluable Patients Achieved Improvements in Multiple Hallmarks of
MYBPC3-Associated HCM

Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom Relief and Improved Cardiac Function at Earlier Timepoint

TN-201 Granted PRIME Designation by EMA; and Pediatric Indication Accepted into FDA’s Rare Disease Evidence Principles Process

Tenaya Management to Host a Webcast Conference Call to Review Results at 8:00 a.m. ET / 5:00 a.m. PT

SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA) reported

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Sym

Wed, 03 Jun 2026 07:00:00 -0400

All Evaluable Patients Achieved Improvements in Multiple Hallmarks of
MYBPC3-Associated HCM

Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom Relief and Improved Cardiac Function at Earlier Timepoint

TN-201 Granted PRIME Designation by EMA; and Pediatric Indication Accepted into FDA’s Rare Disease Evidence Principles Process

Tenaya Management to Host a Webcast Conference Call to Review Results at 8:00 a.m. ET / 5:00 a.m. PT

SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA) reported

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Sym

Wed, 03 Jun 2026 07:00:00 -0400

All Evaluable Patients Achieved Improvements in Multiple Hallmarks of
MYBPC3-Associated HCM

Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom Relief and Improved Cardiac Function at Earlier Timepoint

TN-201 Granted PRIME Designation by EMA; and Pediatric Indication Accepted into FDA’s Rare Disease Evidence Principles Process

Tenaya Management to Host a Webcast Conference Call to Review Results at 8:00 a.m. ET / 5:00 a.m. PT

SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA) reported

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Sym

Wed, 03 Jun 2026 07:00:00 -0400

All Evaluable Patients Achieved Improvements in Multiple Hallmarks of
MYBPC3-Associated HCM

Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom Relief and Improved Cardiac Function at Earlier Timepoint

TN-201 Granted PRIME Designation by EMA; and Pediatric Indication Accepted into FDA’s Rare Disease Evidence Principles Process

Tenaya Management to Host a Webcast Conference Call to Review Results at 8:00 a.m. ET / 5:00 a.m. PT

SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA) reported

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Sym

Wed, 03 Jun 2026 07:00:00 -0400

All Evaluable Patients Achieved Improvements in Multiple Hallmarks of
MYBPC3-Associated HCM

Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom Relief and Improved Cardiac Function at Earlier Timepoint

TN-201 Granted PRIME Designation by EMA; and Pediatric Indication Accepted into FDA’s Rare Disease Evidence Principles Process

Tenaya Management to Host a Webcast Conference Call to Review Results at 8:00 a.m. ET / 5:00 a.m. PT

SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA) reported

Tenaya Therapeutics to present MyPEAK-1 trial data June 3

Tue, 02 Jun 2026 16:30:30 -0400

Tenaya Therapeutics Inc. (NASDAQ: TNYA) announced it will report interim data from its MyPEAK-1 Phase 1b/2 trial of TN-201 gene therapy for adults with MYBPC3-associated hypertrophic cardiomyopathy on June 3, 2026.

The company will host a webcast at 8:00 a.m. ET to review data from Cohort 1 and Cohort 2 of the ongoing trial, according to the company's statement.

TN-201 is an adeno-associated virus serotype 9-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells through a single intravenous infusion. The treatment targets MYBPC3-associated hypertrophic cardiomyopathy, a condition affecting approximately 120,000 patients in the United States.

The U.S. Food

Tenaya Therapeutics to present MyPEAK-1 trial data June 3

Tue, 02 Jun 2026 16:30:30 -0400

The company will host a webcast at 8:00 a.m. ET to review data from Cohort 1 and Cohort 2 of the ongoing trial, according to the company's statement.

The U.S. Food

Tenaya Therapeutics to present MyPEAK-1 trial data June 3

Tue, 02 Jun 2026 16:30:30 -0400

The company will host a webcast at 8:00 a.m. ET to review data from Cohort 1 and Cohort 2 of the ongoing trial, according to the company's statement.

The U.S. Food

Tenaya Therapeutics to present MyPEAK-1 trial data June 3

Tue, 02 Jun 2026 16:30:30 -0400

The company will host a webcast at 8:00 a.m. ET to review data from Cohort 1 and Cohort 2 of the ongoing trial, according to the company's statement.

The U.S. Food

Tenaya Therapeutics to present MyPEAK-1 trial data June 3

Tue, 02 Jun 2026 16:30:30 -0400

The company will host a webcast at 8:00 a.m. ET to review data from Cohort 1 and Cohort 2 of the ongoing trial, according to the company's statement.

The U.S. Food

Tenaya Therapeutics to present MyPEAK-1 trial data June 3

Tue, 02 Jun 2026 16:30:30 -0400

The company will host a webcast at 8:00 a.m. ET to review data from Cohort 1 and Cohort 2 of the ongoing trial, according to the company's statement.

The U.S. Food

Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026

Tue, 02 Jun 2026 16:30:00 -0400

SOUTH SAN FRANCISCO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it will report new interim data from Cohort 1 and Cohort 2 of the ongoing MyPEAK™-1 Phase 1b/2 trial of TN-201 gene therapy for adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM) on Wednesday, June 3, 2026.

Webcast Details:

Tenaya Therapeutics will host a live webcast to review the new data from MyPEAK™-1